Regenerative medicine using biotherapy and bioprinting is providing much hope for previously irreversible conditions such as burns, muscle damage, and cancer. Cells and cellular environments are extremely difficult to reproduce once they are damaged, and much of regenerative medicine focuses on how to repair what our bodies originally made so easily. 3D cell production, versus 2D cell production, mimics the organic environment of our bodies to produce cells. In biotherapy, living organisms are used as the starter in this process.
The complexity in the specificity of our cells is part of why it is so difficult to reverse cell damage. Thus, stem cells are valuable biological material due to their ability to differentiate into any type of cell based on their environment and genetic factors. A stem cell starts out as a blank slate, and by receiving environmental and genetic signals, can become virtually anything in the human body, from a kidney to a blood cell to a muscle in the leg.
Placental stem cells are organically derived and the natural byproduct during a birth. Instead of being discarded, they can provide a very important product for placental cell therapy, which helps direct cells toward regeneration and promotes healing. In biotherapy, these placental stem cells can be very valuable for the cell production process.
Pluristem, a company quickly gaining international presence, produces 3D cultured placental stem cell therapies for various conditions. The company uses a 3D platform to produce their line of PLX products, mimicking the environment of the human body for cell production. This cell therapy is developed to provide cell therapy which is easy to use and does not require genetic or tissue matching. Once the therapy is administered, it promotes the body to heal itself in the target area.
Pluristem products provided regenerative therapy for a variety previously potentially irreversible conditions. Among these is acute radiation syndrome (ARS), which involves irreversible damage to organs and bone marrrow from radiation exposure. Pluristem also aims to provide therapy for vascular conditions such as critical limb ischemia, intermittent claudication, and pulmonary arterial hypertension, all which are dangerous and can lead to decreased life span or surgery.
Pluristem is currently in its clinical trial phase, with collaborations with several universities and industry partners, including the NIH.